Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T12566 |
PS10
|
PDK | PI3K/Akt/mTOR signaling |
PS10 is a ATP-competitive inhibitor of pan-PDK(PDK2, PDK4, PDK1, and PDK3 with IC50 of 0.8 μM, 0.76 μM, 2.1 μM and 21.3 μM , respectively). | |||
T22888 |
KC01
|
Others | Others |
KC01 is an effective and selective inhibitor of ABHD16A. By measuring competitive gel-based ABPP (IC50 values of inhibition of ABHD16A by KC01 and KC02: ~0.2–0.5 μM and >10 μM, respectively). Testing by a PS substrate assay, IC50 values of inhibition of h | |||
T65387 | Paromomycin, sulfate (1:1) | ||
Paromomycin (Sulfate Salt) is an aminoglycoside that is active against Gram-negative and many Gram-positive bacteria as well as some protozoa and cestodes. Paromomycin in combination with sodium stibogluconate has proven to be effective in African and Indian VL (visceral leishmaniasis) and improves survival in African VL[3]. PS (Paromomycin Sulfate) is effective for elimination of B. coli without hematological side effects[4]. The activity of phosphoglucose isomerase was slightly inhibited by 10... | |||
T37581 | SCIO 469 hydrochloride | ||
Selective, ATP-competitive p38 inhibitor (IC50 = 9 nM for p38α in vitro). Displays approximately 10-fold selectivity for p38α over p38β and 2000-fold selectivity for p38α over 20 other kinases. Reduces p38α phosphorylation in multiple myeloma cells in vitro and in vivo; activity results in decreased tumor burden and angiogenesis in murine models of multiple myeloma. Also enhances bortezomib-induced cytotoxicity against multiple myeloma cells. Hideshima et al (2004) p38 MAPK inhibition enhances P... |